中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(11): 2329-2335

Value of neutrophil-to-lymphocyte and platelet ratio in predicting recompensation in patients with hepatitis B cirrhotic ascites and establishment of a nomogram model

DOI: 10.12449/JCH251120
  • 1.

    Department of Gastroenterology，The Affiliated Hospital of Southwest Medical University，Luzhou，Sichuan 646000，China

  • 2.

    Department of Gastroenterology，The General Hospital of Western Theater Command of Chinese PLA，Chengdu 610083，China

Research funding:

Project of the General Hospital of Western Theater Comm (2024-YGLC-B05)

More Information
  • Corresponding author: TANG Shanhong， tangshanhong@swjtu.edu.cn （ORCID： 0000-0001-6652-2942）
  • Received Date: 2025-04-23
  • Accepted Date: 2025-06-06
  • Published Date: 2025-11-25
    Abstract
  •   Objective  To investigate the association between neutrophil-to-lymphocyte and platelet ratio （NLPR） and recompensation in patients with hepatitis B cirrhotic ascites， and to establish an individualized risk prediction model.  Methods  The patients with hepatitis B cirrhotic ascites who were hospitalized in Department of Gastroenterology， The General Hospital of Western Theater Command of Chinese PLA， from January 2015 to December 2022 were enrolled. General information and laboratory markers were collected， and NLPR was calculated. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test or the chi-square test with correction was used for comparison of categorical data between two groups. The subjects were randomly divided into a training set and a validation set at a ratio of 7∶3. In the training set， univariate and multivariate binary Logistic regression analyses were used to investigate the independent influencing factors for recompensation in patients with hepatitis B cirrhotic ascites， and a nomogram was established； the receiver operating characteristic （ROC） curve was used to assess the value of the new model in predicting recompensation in patients with hepatitis B cirrhotic ascites， and the Delong test was used for comparison of the area under the ROC curve （AUC）. The calibration curve and the decision curve were plotted for the model， and the model was assessed in terms of degree of fitting and predictive benefits.  Results  A total of 360 patients were enrolled， among whom134 achieved recompensation. There were 252 patients in the training set and 108 patients in the validation set， and there were no significant differences in baseline characteristics between the two groups （all P>0.05）. The Logistic regression analysis showed that the onset of hepatic encephalopathy （odds ratio ［OR］=0.066， 95% confidence interval ［CI］： 0.008 — 0.545， P=0.012）， NLPR （OR=0.950， 95%CI： 0.912 — 0.989， P=0.012）， alpha-fetoprotein （OR=1.012， 95%CI： 1.005 — 1.020， P<0.001）， and albumin （OR=1.096， 95%CI： 1.031 — 1.166， P=0.003） were independent influencing factors for recompensation in patients with hepatitis B cirrhotic ascites. The above four factors were included in a nomogram predictive model， which had an AUC of 0.776， a sensitivity of 66.5%， and a specificity of 76.3% in the training set and an AUC of 0.746， a sensitivity of 63.4%， and a specificity of 75.7% in the validation set， while Model for End-Stage Liver Disease score， Child-Pugh score， and albumin-bilirubin score had an AUC of 0.574， 0.628， and 0.621， respectively. The nomogram model had a better performance than the other three scores in predicting recompensation in patients with hepatitis B cirrhotic ascites （Z=4.191， 3.369， and 3.527， P<0.001， P=0.001， and P<0.001）. The calibration curve and the decision curve showed that the model had a good degree of fitting， and the decision made using this model could bring net benefits.  Conclusion  NLPR has a good value in predicting recompensation in patients with hepatitis B cirrhotic ascites， and the nomogram model established can help to predict recompensation in such patients in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    LI Z, ZHU JF, OUYANG H. Recent insights into contributing factors in the pathogenesis of cirrhotic ascites[J]. Front Med(Lausanne), 2024, 11: 1376217. DOI: 10.3389/fmed.2024.1376217.
    [2]
    D’AMICO G, PASTA L, MORABITO A, et al. Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients[J]. Aliment Pharmacol Ther, 2014, 39( 10): 1180- 1193. DOI: 10.1111/apt.12721.
    [3]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [4]
    FENG G, SONG JJ, YE F, et al. Recompensation of liver cirrhosis: Current status and challenges[J]. J Clin Hepatol, 2023, 39( 10): 2464- 2469. DOI: 10.3969/j.issn.1001-5256.2023.10.027.

    冯巩, 宋娟娟, 叶峰, 等. 肝硬化再代偿: 现状与挑战[J]. 临床肝胆病杂志, 2023, 39( 10): 2464- 2469. DOI: 10.3969/j.issn.1001-5256.2023.10.027.
    [5]
    SOHRABPOUR AA, MOHAMADNEJAD M, MALEKZADEH R. Review article: The reversibility of cirrhosis[J]. Aliment Pharmacol Ther, 2012, 36( 9): 824- 832. DOI: 10.1111/apt.12044.
    [6]
    TREBICKA J, AMOROS A, PITARCH C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis[J]. Front Immunol, 2019, 10: 476. DOI: 10.3389/fimmu.2019.00476.
    [7]
    BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy: Who and why?[J]. Liver Int, 2015, 35( Suppl 1): 78- 81. DOI: 10.1111/liv.12710.
    [8]
    SU X, ZHAO SG, ZHANG N. Admission NLPR predicts long-term mortality in patients with acute ischemic stroke: A retrospective analysis of the MIMIC-III database[J]. PLoS One, 2023, 18( 8): e0283356. DOI: 10.1371/journal.pone.0283356.
    [9]
    WANG HB, ZHANG R, XU J, et al. Development of a prognosis prediction model for pediatric sepsis based on the NLPR[J]. J Inflamm Res, 2024, 17: 7777- 7791. DOI: 10.2147/JIR.S479660.
    [10]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [11]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites in cirrhosis(2023 version)[J]. Chin J Hepatol, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011.

    中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011.
    [12]
    WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037.
    [13]
    AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70( 1): 9- 29. DOI: 10.1136/gutjnl-2020-321790.
    [14]
    AIROLA C, VARCA S, DEL GAUDIO A, et al. The covert side of ascites in cirrhosis: Cellular and molecular aspects[J]. Biomedicines, 2025, 13( 3): 680. DOI: 10.3390/biomedicines13030680.
    [15]
    TANG JJ, YAN ZJ, FENG QY, et al. The roles of neutrophils in the pathogenesis of liver diseases[J]. Front Immunol, 2021, 12: 625472. DOI: 10.3389/fimmu.2021.625472.
    [16]
    LI Q, GUO HH. Research advances in association between blood neutrophil/lymphocyte ratio and prognosis of related liver diseases[J]. J Clin Hepatol, 2017, 33( 4): 780- 784. DOI: 10.3969/j.issn.1001-5256.2017.04.041.

    李乔, 郭宏华. 血中性粒细胞/淋巴细胞比率与相关肝脏疾病预后关系的研究进展[J]. 临床肝胆病杂志, 2017, 33( 4): 780- 784. DOI: 10.3969/j.issn.1001-5256.2017.04.041.
    [17]
    ZHANG X, ZHANG L, TANG SH. The prognostic value of neutrophil lymphocyte ratio and its dynamic changes in the treatment of chronic hepatitis B associated acute liver failure with artificial liver[J]. J Pract Med, 2022, 38( 18): 2341- 2345. DOI: 10.3969/j.issn.1006-5725.2022.18.016.

    张雪, 张亮, 汤善宏. 中性粒细胞-淋巴细胞比值及其动态变化在人工肝治疗乙肝相关慢加急性肝衰竭预后的评估价值[J]. 实用医学杂志, 2022, 38( 18): 2341- 2345. DOI: 10.3969/j.issn.1006-5725.2022.18.016.
    [18]
    ZHONG LK, ZHANG G, LUO SY, et al. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B[J]. J Clin Lab Anal, 2020, 34( 7): e23270. DOI: 10.1002/jcla.23270.
    [19]
    HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years[J]. Gastroenterology, 2006, 131( 6): 1743- 1751. DOI: 10.1053/j.gastro.2006.09.020.
    [20]
    VARSHNEY A, GUPTA R, VERMA SK, et al. Alpha-fetoprotein as a prognostic marker in acute liver failure: A pilot study[J]. Trop Doct, 2017, 47( 3): 202- 205. DOI: 10.1177/0049475516653891.
    [21]
    WANG XP, SUN MY, YANG XJ, et al. Value of liver regeneration in predicting short-term prognosis for patients with hepatitis B-related acute-on-chronic liver failure[J]. Biomed Res Int, 2020, 2020: 5062873. DOI: 10.1155/2020/5062873.
    [22]
    BALDASSARRE M, NALDI M, ZACCHERINI G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications[J]. Hepatology, 2021, 74( 4): 2058- 2073. DOI: 10.1002/hep.31798.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (6) PDF downloads(3) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return